Clinical Outcomes in HIV+/HCV+ Co-infected Kidney Transplant Recipients in the Pre- and Post-direct Acting Antiviral (DAA) Therapy Eras: 10-year Single-center Experience. (4th October 2017)

• Record Type: Journal Article
• Authors: Anjan, Shweta; Camargo, Jose F; Morris, Michele I; Abbo, Lilian M; Simkins, Jacques; Guerra, Gisele; Kupin, Warren; Mattiazzi, Adela; Chen, Linda; Burke, George; Figueiro, Jose; Ruiz, Phillip; Bhamidimarri, Kalyan; Roth, David
• Is Part Of: Open forum infectious diseases. Volume 4(2017)Supplement 1
• Page Start: S728
• Page End: S729
• Publication Date: 2017-10-04
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx163.1965
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Clinical outcomes in HIV + /HCV + co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year Single-center experience Background: Previous studies have shown worse patient and graft survival following kidney transplant (KT) in HIV + /HCV + co-infected patients compared with HIV + /HCV - recipients. However, these studies were conducted prior to the advent of DAA therapy and data in the modern era is lacking. Methods: Single-center retrospective study of HIV + /HCV + co-infected patients who underwent deceased donor KT between 2007 and 2017. All patients had ART-induced HIV viral load suppression at the time of transplant. Results: A total of 12 consecutive HIV + /HCV + recipients were identified (Table 1). Nine patients were HCV viremic at the time of transplant. Median time of follow-up was 371 days. Six patients were transplanted in the DAA era (i.e., after 2013), 4 of them had HCV + donors; all received DAA therapy, 5 of them post-transplant (median time from KT to DAA: 63 days; Table 2). Patient and death censored graft survival at 9 months were 92% and 83% for the entire cohort, and 100% for the subgroup of patients transplanted in the DAA era - with no episodes of rejection nor infectious complications (Table 3). Conclusion: Outcomes of HIV + /HCV + KT recipients, including HCV + to HCV + transplants, in the DAA era were excellent in this cohort. Larger studies in this area are needed. Disclosures: M. I. Morris, Novartis: Consultant, Consulting fee. Optimer: Investigator, Research support. Merck: Investigator, Research support. Chimerix: Investigator and Scientific Advisor, Consulting fee and Research support